Geri Dön

Neoadjuvan kemoterapi alan meme kanserli hastalarda androjen reseptör ekspresyonunun tedavi yanıtla ilişkisi ve prognostik önemi

The relationship between androgen receptor expression and treatment response, as well as the prognostic significance, in breast cancer patients receiving neoadjuvant chemotherapy

PDF İndir

  1. Tez No: 805825
  2. Yazar: ABDULLAH ÜMİT
  3. Danışmanlar: PROF. DR. ALİ MURAT TATLI
  4. Tez Türü: Tıpta Uzmanlık
  5. Konular: Onkoloji, İç Hastalıkları, Oncology, Internal diseases
  6. Anahtar Kelimeler: Breast Cancer, Neoadjuvant Chemotherapy, Androgen Receptor, Pathological Complete Response, Prognosis, Survival
  7. Yıl: 2023
  8. Dil: Türkçe
  9. Üniversite: Akdeniz Üniversitesi
  10. Enstitü: Tıp Fakültesi
  11. Ana Bilim Dalı: İç Hastalıkları Ana Bilim Dalı
  12. Bilim Dalı: Belirtilmemiş.
  13. Sayfa Sayısı: 240

Özet

GİRİŞ: Meme kanseri; klinik, patolojik ve moleküler açıdan çeşitli spektrumları içeren, farklı biyolojik alt tiplerden oluşan heterojen bir hastalık grubudur. Küresel olarak her yıl iki milyondan fazla vakaya neden olan ve kadınlarda en sık teşhis edilen malignitedir. Aynı zamanda kadınlarda kanser ölümlerinin önde gelen nedenlerinden birisidir. Meme kanserinde bilinen tüm prognostik / prediktif belirteçler ve sınıflamalar göz önüne alındığında; aynı tedavi yöntemleri uygulandığında bile hastalar arasında tedaviye cevap, rekürrensler, tümör davranışı ve genel prognoz açısından önemli farklılıklar olduğu gözlenmektedir. Bu durumlar prognozu etkileyen başka faktörlerin de bulunduğu düşüncesini ortaya çıkarmaktadır. Meme tümörlerindeki bu heterojenitenin yol açmış olduğu hedefe yönelik tedavilerdeki zorluklar aşılmaya çalışılmaktadır. Androjen reseptörü, tüm meme kanseri tiplerinde en sık eksprese edilen (%47-%90) seks steroid reseptörü olmasına rağmen androjenlerin ve androjen reseptörü ekspresyonunun; meme kanserindeki prognostik ve prediktif değerleri ile klinik olarak hastalık seyri ve tedavi yanıttaki önemi hakkında yeterli klinik çalışma mevcut değildir. Literatürde, özellikle neoadjuvan kemoterapi alan hastalarda AR durumunun önemini açığa çıkarmak için yapılan çalışma sayısı azdır. AMAÇ: Bu çalışma androjen reseptör ekspresyonu durumunun, meme kanserindeki diğer biyolojik belirteçler ile olan ilişkisini, klinik sonuçlar üzerine etkili prediktif ve prognostik önemini, neoadjuvan kemoterapi sonrası patolojik yanıtı tahmin etme gücü ve sağkalım üzerine etkilerinin gösterilmesi amaçlanmıştır. Özellikle tedavi seçeneği sınırlı ve mevcut tedavilere karşı dirençli olan meme tümörlerinde geliştirilebilecek olan hedefe yönelik yeni tedavi yöntemleri için androjen reseptörünün de seçenekler arasında bulunabileceğinin, mevcut diğer tedavilere verilen yanıtlarla prediktif ilişkisinin ve neoadjuvan tedavilere daha iyi yanıt verecek hastaların belirlenmesinde rutin kullanılabilecek ek bir prognostik belirteç olarak öneminin gösterilmesi amaçlanmıştır. GEREÇ ve YÖNTEM: Bu çalışma retrospektif olarak neoadjuvan kemoterapi alan evre 2 ve evre 3 meme kanserli hastalarda tüm moleküler alt tipleri kapsayacak şekilde planlanmıştır. Akdeniz Üniversitesi Tıp Fakültesi Hastanesi Tıbbi Onkoloji kliniğinde meme kanseri tanısıyla takip edilip Neoadjuvan kemoterapi almış ve sonrasında cerrahi olmuş toplam 176 hasta çalışmaya dahil edilmiştir. Androjen reseptör antikorları ile IHK olarak meme tümör dokularında AR ekspresyonu durumu incelenerek; Androjen reseptörünün, çeşitli klinopatolojik parametreler, neoadjuvan kemoterapi sonrası patolojik yanıt durumu ve sağkalım durumları ile ilişkisi analiz edilmiştir. Androjen reseptörü antikoru ile IHK olarak tümör hücrelerindeki %1 ve üzeri nükleer boyanmayı AR ekspresyonu pozitif durum olarak kabul edilmiştir. Neoadjuvan kemoterapi sonrası patolojik yanıt durumları RCB (Residual Cancer Burden) skorlama sistemi kullanarak değerlendirilmiştir. BULGULAR: Bulgular: Çalışmaya katılan hastaların tamamı kadındır ve yaş ortalaması 49,8±10,5 yıldır. Hastaların %87,5'i IDC, NST; %4,5'i ILC tipindeydi. Hastaların moleküler subtiplerine göre sırasıyla %32,4'ü Luminal B HER2 negatif, %27,8'i Luminal B HER2 pozitif, %18,8'i TNMK, %14,2'si HER2 pozitif (non-luminal) ve %6,8'i ise Luminal A subtipinde saptandı. Çalışmaya katılan hastaların %66,5'i HR pozitif iken %42'si HER2 pozitif izlendi. Hastaların tanı anı doku biyopsilerinde ortalama TİL yüzdesi %27±28,7 saptandı. Hastaların neoadjuvan kemoterapi öncesi %59,1'inde AR ekspresyonu pozitif saptandı. Androjen reseptörü pozitifliği; daha küçük tümör boyutu (p=0,024), daha düşük histolojik grade (p=0,022), daha düşük Ki-67 skoru (p=0,004), hormon reseptör pozitifliğinde artış, triple negatif meme kanseri sıklığında azalma gibi olumlu prognostik faktörler ile istatistiksel anlamlı ilişkili gösterdi. Hastaların %42'sinde neoadjuvan kemoterapi sonrası patolojik tam yanıt saptandı. Androjen reseptörü pozitif grupta patolojik tam yanıt oranı %44,2 iken androjen reseptörü negatif olan grupta %38,9'du. Tüm hasta grubunda androjen reseptör pozitifliği ile patolojik tam yanıt arasında istatiksel anlamlı ilişki saptanmadı. Luminal B HER2 + hastalarda, androjen reseptör pozitif boyanma yüzdesi arttıkça tümör boyutunda küçülme izlendi (p=0,031). Triple negatif meme kanserli hastalarda ise androjen reseptörpozitiflik yüzdesinin artması; yaşın ileri olması, daha büyük rezidü invaziv tümör boyutu ve daha yüksek RCB skoru ile ilişki gözlendi (sırasıyla p=0,020; p=0,007; p=0,017). Luminal B HER2 + grupta androjen reseptör pozitif olan hastalarda neoadjuvan kemoterapi sonrası rezidü invaziv tümör boyutu ve RCB skoru androjen reseptör negatif olan hastalara göre daha düşük saptandı (sırasıyla; p=0,037 ve p=0,037). Triple negatif meme kanserli grupta androjen reseptör pozitif olan hastalarda, neoadjuvan kemoterapi sonrası RCB skorunda ve tümör boyutunda androjen reseptör negatif olan hastalara göre istatistiksel anlamlı yükseklik saptandı (sırasıyla; p=0,019 ve p=0,005). Patolojik tam yanıt olan hastalarda neoadjuvan kemoterapi öncesi ortanca TİL yüzdesi patolojik tam yanıt olmayan hastalara göre daha yüksek saptandı (p=0,006). Yapılan sağkalım analizi çalışmalarında tüm hastalarda androjen reseptörü ekspresyonu pozitifliği ile genel sağkalım ve hastalıksız sağkalım arasında anlamlı ilişki saptanmadı. Hastalar androjen reseptörü boyanma yüzdesine göre sınıflandırıp sağkalım açısından karşılaştırıldığında; androjen reseptörü boyanma yüzdesi >%50 olan hastalarda genel sağkalım hızının, androjen reseptörü boyanma yüzdesi %0-50 olan hastalara göre daha düşük olduğu saptandı (p=0,041). Ancak genel sağkalım üzerine etkili risk faktörlerinin multivariate COX Regresyon Analizi ile değerlendirilmesi sonuçlarında androjen reseptörü boyanma yüzdesinin sağkalıma etkisi gösterilemedi. Multivariate COX Regresyon analizi sonucuna göre nüks olan hastaların 8 kat, 50 yaş üzerindeki hastaların ise 5 kat fazla mortal seyrettiği gösterildi. Yapılan sağkalım analizlerinde TİL boyanma yüzdesinin genel sağkalım üzerine anlamlı bir etkisi saptanmadı. Ancak TIL skoru >%10 olan hastalarda 3 yıllık ve 5 yıllık hastalıksız sağkalım hızlarında TIL skoru

Özet (Çeviri)

Introduction: Breast cancer is a disease group that encompasses various spectra clinically, pathologically, and molecularly, consisting of different biological subtypes. Globally, it is the most commonly diagnosed malignancy, causing over two million new cases each year. Breast cancer, along with lung, stomach, liver, and colon cancer, plays a significant role in cancer-related mortality. Neoadjuvant therapy allows for reducing the extent of surgery, preserving axillary lymph nodes, and achieving lower complications and better cosmetic outcomes. Additionally, neoadjuvant therapy carries predictive characteristics, enabling the anticipation of various information about the treatment regimen that is expected to provide a better response than the available treatment modalities in case of recurrence during postsurgical follow-ups. It also allows for early assessment of treatment response, thus holding predictive value. Breast cancer has been divided into different molecular subtypes based on gene expression analyses and molecular studies, which have implications for prognosis, treatment management, and clinical perspectives. The therapeutic, predictive, and prognostic importance of molecular markers such as ER, PR, and HER2 has been well-established for predicting clinical outcomes and managing the disease. However, despite considering all these parameters and classifications, and even with the application of the same treatment methods, significant differences in treatment response, recurrences, tumor behavior, and overall prognosis are observed among patients. This suggests the presence of other factors that influence prognosis. Efforts are being made to overcome the challenges in targeted therapies caused by the heterogeneity of breast tumors. Objective: Despite androgen receptor (AR) being the most commonly expressed sex steroid receptor (47%-90%) in all types of breast cancer, there is a lack of sufficient clinical studies regarding the prognostic and predictive values of androgens and AR expression in the diagnosis of the disease, as well as their clinical significance in disease progression and treatment response in breast cancer. In the literature, there are few studies specifically focusing on the importance of AR status in patients receiving neoadjuvant chemotherapy (NACT). This study aims to demonstrate the relationship between AR expression and other biological markers in breast cancer, their predictive and prognostic significance on clinical outcomes, their ability to predict pathological response after NACT, and their impact on survival. Materials and Methods: This study was planned retrospectively to include all molecular subtypes of stage 2 and stage 3 breast cancer patients who received neoadjuvant chemotherapy (NAKT). A total of 176 patients who were diagnosed with breast cancer and followed up at the Medical Oncology Clinic of Akdeniz University Faculty of Medicine Hospital, received neoadjuvant chemotherapy, and underwent subsequent surgery were included in the study. The data regarding the demographic, clinical, and pathological characteristics of the included patients were retrospectively collected through file scanning method from the hospital's medical record systems and archives.The AR expression status in breast tumor tissues was examined using androgen receptor antibodies through immunohistochemical analysis. The relationship between androgen receptor and various clinical and pathological parameters, pathological response after NACT, and survival outcomes was analyzed. Nuclear staining of 1% or higher in tumor cells with AR antibody was considered as a positive AR expression status. The pathological response after neoadjuvant chemotherapy was evaluated using the Residual Cancer Burden (RCB) scoring system. The overall survival duration is defined as the time between the diagnosis date and the date of death or the time until the end of the study/last visit if the patient is still alive. Disease-free survival duration is defined as the time between the date of surgery after NACT and the date of the first recurrence, or if no recurrence occurs, the time between the date of surgery and the date of death, or if the patient is in remission, the time between the date of surgery and the end of the study/last visit. Results: All patients included in the study were female, with a mean age of 49.8±10.5 years. The average tumor size before neoadjuvant chemotherapy was 39.1±19.3 mm. Among the patients, 87.5% had invasive ductal carcinoma (IDC),not otherwise specified (NST), and 4.5% had invasive lobular carcinoma (ILC). When analyzing the distribution of patients based on molecular subtypes, 32.4% were identified as Luminal B HER2-negative, 27.8% as Luminal B HER2-positive, 18.8% as triple negative, 14.2% as HER2-positive (non-luminal), and 6.8% as Luminal A subtype. Among the participants, 66.5% were hormone receptor (HR) positive, while 42% were HER2 positive. The mean percentage of tumorinfiltrating lymphocytes (TIL) in the diagnostic tissue biopsies of the patients was found to be 27%±28.7. When the pre-NACT tissue biopsy samples of the patients were examined using immunohistochemical analysis methods, positive AR expression was detected in 59.1% of the patients. In our study, positive AR expression was found to be significantly associated with favorable prognostic factors such as smaller tumor size (p=0.024), lower histological grade (p=0.022), lower Ki-67 score (p=0.004), and an increase in hormone receptor positivity and a decrease in triple-negative phenotype. Among the 176 patients included in the study, pathological complete response (pCR) was observed in 74 (42%) patients. The statistical significance of pCR on disease-free survival (DFS) and overall survival (OS) could not be demonstrated. The pCR rate was 44.2% in the AR-positive group and 38.9% in the AR-negative group. There was no statistically significant relationship between AR positivity and pCR in the entire patient group. In Luminal B HER2+ patients, as the percentage of AR-positive staining increased, tumor size reduction was observed (p=0.031). In triple-negative breast cancer patients, an increase in AR positivity percentage was associated with older age at diagnosis, larger residual invasive tumor size after NACT, and higher RCB score after NACT (p=0.020, p=0.007, p=0.017, respectively). In the Luminal B HER2+ group, patients with positive AR expression had significantly smaller residual invasive tumor size and lower RCB score after NACT compared to patients with negative AR expression (p=0.037 and p=0.037, respectively). In the triple-negative breast cancer group, patients with positive AR expression had statistically higher RCB score and tumor size after NACT compared to patients with negative AR expression (p=0.019 and p=0.005, respectively).When the TIL scores before NACT were compared between the groups with and without pCR, it was found that the median TIL percentage before NACT was significantly higher in patients with pCR compared to those without pCR (p=0.006).In our study, the survival analysis showed a 1-year disease-free survival (DFS) rate of 100%, a 3-year DFS rate of 95.2%, and a 5-year DFS rate of 91.7% for all patients. However, no significant relationship was found between AR expression positivity and DFS or overall survival (OS). When patients were classified based on AR staining percentage and compared using the Log-Rank analysis, it was observed that patients with AR staining percentage >50% had a lower DFS rate compared to those with AR staining percentage of 0-50% (p=0.041). However, the impact of AR staining percentage on DFS could not be demonstrated as an influential risk factor. This indicates a significantly increased mortality risk in patients who experienced recurrence and in those who were above 50 years old. In the survival analysis conducted on the patients included in the study, no significant effect of TIL (Tumor-Infiltrating Lymphocyte) staining percentage on overall survival (GSK) was observed. However, when comparing the DFS(Disease-Free Survival) rates based on TIL staining percentage, a statistically significant increase in the 3-year and 5-year DFS rates was observed in patients with TIL score >10% compared to those with TIL score 10%) is associated with improved disease-free survival at the 3-year and 5-year follow-up periods. Conclusion: When evaluating the impact of AR expression status on pCR in the entire patient group, no significant association was found between AR expression status and pCR. However, when evaluating treatment response in different molecular subtypes, AR positivity was found to be associated with a better pathological response to NACT in Luminal B HER2-positive patients and a worse pathological response to NACT in TNBC patients. These findings suggest that the role of AR expression in treatment response may vary depending on the molecular subtypes. We have demonstrated that increasing positive staining percentage of AR is associated with better pathological response to NACT and smaller residual invasive tumor size in Luminal B HER2+ patients, indicating favorable prognostic outcomes. Our study has shown that AR expression in HER2-positive patients is associated with positive clinicopathological characteristics, and based on these clinicopathological data, we have shown that Luminal B HER2+/AR+ patients have a better prognosis compared to Non-Luminal HER2+/AR+ patients. This finding constitutes one of the most significant contributions of our study to the literature.On the contrary, in TNBC, we found that increasing positive staining percentage of AR is associated with a decrease in pathological response to NACT and worse prognostic characteristics. These findings suggest that AR exhibits different biological behaviors in molecular subtypes of breast cancer and that the predictive and prognostic significance of AR expression in predicting pathological response to NACT varies among molecular subtypes. In our study, positive AR expression was found to be significantly associated with favorable prognostic factors such as smaller tumor size (p=0.024), lower histological grade (p=0.022), lower Ki-67 score (p=0.004), increased HR positivity, and decreased TNBC subtype. Additionally, AR-positive patients showed an increased frequency of HER2 positivity (p=0.016) and HR positivity (p=0.001), as well as a lower frequency of TNBC subtype and a higher frequency of Luminal A and Luminal B HER2+ subtypes (p=0.001). These findings indicate the predictive significance of AR positivity in patients eligible for targeted therapies. These results suggest that AR expression can be considered as a favorable prognostic and predictive marker in patients with breast cancer receiving NACT. In our survival analysis studies, the 1-year DFS rate was 100%, the 3-year DFS rate was 95.2%, and the 5-year DFS rate was 91.7% for all patients. However, no significant association was found between AR expression positivity and DFS or overall survival (OS). Due to the limited number of patients and total events encountered in specific molecular subtypes, survival analyses comparing AR positive and AR-negative groups could not be performed. Additionally, when patients were classified based on AR staining percentage and compared using the Log Rank test, it was found that patients with AR staining percentage >50% had lower DFS compared to those with AR staining percentage of 0-50% (p=0.041). However, when evaluating the impact of influential risk factors on DFS using multivariate Cox regression analysis, the effect of AR staining percentage on survival could not be demonstrated. In our study, we demonstrated that high tumor-infiltrating lymphocyte (TIL) percentages increased the pathological response to neoadjuvant chemotherapy (NACT) independently of AR expression in all molecular subtypes. Specifically, TIL percentages of 10% or higher were associated with positive prognostic features on disease-free survival (DFS). These findings suggest that increased TIL presence in the tumor microenvironment is associated with enhanced tumor immunity and improved treatment response. In conclusion, we believe that increasing the number of patients in our study, extending the clinical follow-up period, and encountering more events would provide a clearer understanding of the impact of AR positivity and AR staining percentage on the pathological response to NACT and their prognostic effects on survival, both for the entire study population and within specific molecular subtypes.

Benzer Tezler

  1. Tez No

    839280

    Neoadjuvan kemoterapi alan Triple Negatif Meme Kanserli hastalarda androjen reseptör ekspresyonunun tedavi yanıtı ve sağkalım üzerine etkileri

    Androgen receptor expression on treatment response and survival in Triple Negative Breast Cancer after neoadjuvant chemotherapy

    SEDA KARAÇAM

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2023

    Genel CerrahiSağlık Bilimleri Üniversitesi

    Genel Cerrahi Ana Bilim Dalı

    PROF. DR. SUAT KUTUN

  2. Tez No

    701244

    Lokal ileri meme kanserli hastalarda neoadjuvan kemoterapi sonrası tümör-infiltre eden lenfosit (TIL) ve androjen reseptör (AR) ekspresyonlarındaki değişim ve rezidü tümör varlığı arasındaki ilişki

    The relationship between the change in the tumor-infilteringlymphocyte (tiltıl of residential tumor after neoadjuvanchemoteraphy in patients with local advanced breast cancer

    VEDAT BUĞRA EROL

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2021

    Onkolojiİstanbul Medipol Üniversitesi

    İç Hastalıkları Ana Bilim Dalı

    PROF. DR. AHMET BİLİCİ

  3. Tez No

    773286

    Neoadjuvan kemoterapi alan meme kanserli hastalarda, klinik sonuçlar üzerine etkili faktörlerin gözden geçirilmesi

    A review of factors affecting clinical outcomes in patients with breast cancer receiving neoadjuvant chemotherapy

    HASAN ÖZDEMİR

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2023

    OnkolojiSağlık Bilimleri Üniversitesi

    İç Hastalıkları Ana Bilim Dalı

    DOÇ. DR. ARİFE ULAŞ

  4. Tez No

    347865

    Neoadjuvan kemoterapı alan meme kanserlı hastalarda NF-KB, survıvın ve Kİ-67 ekspresyonlarının değerlendirilmesi

    Evaluation of NF-KB, survivin and Kİ-67 expressions in breast cancer patients receiving neoadjuvant chemotherapy

    SİNAN DEMİRCİOĞLU

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2013

    OnkolojiNecmettin Erbakan Üniversitesi

    Dahili Tıp Bilimleri Bölümü

    DOÇ. DR. MEHMET ARTAÇ

  5. Tez No

    650723

    Neoadjuvan kemoterapi alan meme kanserli hastalarda patolojik yanıtın manyetik rezonans görüntüleme (MRG) bulgularıyla değerlendirilmesi

    Magnetic resonance imaging (MRI) evaluation of pathologi̇cal response i̇n breast cancer after neoadjuvant chemotherapy

    GÜLÇİN AKKAVAK PALAZ ALI

    Tıpta Uzmanlık

    Türkçe

    Türkçe

    2017

    Radyoloji ve Nükleer Tıpİstanbul Üniversitesi

    Radyoloji Ana Bilim Dalı

    PROF. DR. MENDUH DURSUN

    DR. ÖĞR. ÜYESİ RAVZA SÜMEYYE YILMAZ

Geri Dön